Literature DB >> 19519774

Activation of dopamine D1 receptors blocks phencyclidine-induced neurotoxicity by enhancing N-methyl-D-aspartate receptor-mediated synaptic strength.

Gang Lei1, Noelle C Anastasio, Yu Fu, Volker Neugebauer, Kenneth M Johnson.   

Abstract

Early postnatal blockade of NMDA receptors by phencyclidine (PCP) causes cortical apoptosis in animals. This is associated with the development of schizophrenia-like behaviors in rats later in life. Recent studies show that the mechanism involves a loss of neurotrophic support from the phosphoinositol-3 kinase/Akt pathway, which is normally maintained by synaptic NMDA receptor activation. Here we report that activation of dopamine D1 receptors (D1R) with dihydrexidine (DHX) prevents PCP-induced neurotoxicity in cortical neurons by enhancing the efficacy of NMDAergic synapses. DHX increases serine phosphorylation of the NR1 subunit through protein kinase A activation and tyrosine phosphorylation of the NR2B subunit via Src kinase. DHX enhances recruitment of NR1 and NR2B, but not NR2A, into synapses. DHX also facilitated the synaptic response in cortical slices and this was blocked by an NR2B antagonist. DHX pre-treatment of rat pups prior to PCP on postnatal days 7, 9 and 11 inhibited PCP-induced caspase-3 activation on PN11 and deficits in pre-pulse inhibition of acoustic startle measured on PN 26-28. In summary, these data demonstrate that PCP-induced deficits in NMDA receptor function, neurotoxicity and subsequent behavioral deficits may be prevented by D1R activation in the cortex and further, it is suggested that D1R activation may be beneficial in treating schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19519774      PMCID: PMC2709756          DOI: 10.1111/j.1471-4159.2009.06030.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  60 in total

Review 1.  Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment.

Authors:  Charles R Yang; Long Chen
Journal:  Neuroscientist       Date:  2005-10       Impact factor: 7.519

Review 2.  NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia.

Authors:  J W Olney; N B Farber
Journal:  Neuropsychopharmacology       Date:  1995-12       Impact factor: 7.853

3.  Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies.

Authors:  W G Tingley; M D Ehlers; K Kameyama; C Doherty; J B Ptak; C T Riley; R L Huganir
Journal:  J Biol Chem       Date:  1997-02-21       Impact factor: 5.157

4.  Dopamine receptor stimulation modulates AMPA receptor synaptic insertion in prefrontal cortex neurons.

Authors:  Xiu Sun; Yun Zhao; Marina E Wolf
Journal:  J Neurosci       Date:  2005-08-10       Impact factor: 6.167

5.  NMDA receptor subunits epsilon 1 (NR2A) and epsilon 2 (NR2B) are substrates for Fyn in the postsynaptic density fraction isolated from the rat brain.

Authors:  T Suzuki; K Okumura-Noji
Journal:  Biochem Biophys Res Commun       Date:  1995-11-13       Impact factor: 3.575

6.  Modulation of memory fields by dopamine D1 receptors in prefrontal cortex.

Authors:  G V Williams; P S Goldman-Rakic
Journal:  Nature       Date:  1995-08-17       Impact factor: 49.962

7.  Effects of phencyclidine (PCP) and (+)MK-801 on sensorimotor gating in CD-1 mice.

Authors:  P Curzon; M W Decker
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1998-01       Impact factor: 5.067

8.  Activation of D1, but not D2 receptors potentiates dizocilpine-mediated disruption of prepulse inhibition of the startle.

Authors:  Marco Bortolato; Gian Nicola Aru; Mauro Fà; Roberto Frau; Marco Orrù; Paola Salis; Alberto Casti; Grant Christopher Luckey; Giampaolo Mereu; Gian Luigi Gessa
Journal:  Neuropsychopharmacology       Date:  2005-03       Impact factor: 7.853

9.  Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated.

Authors:  C Cepeda; N A Buchwald; M S Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

10.  Atypical anti-schizophrenic drugs prevent changes in cortical N-methyl-D-aspartate receptors and behavior following sub-chronic phencyclidine administration in developing rat pups.

Authors:  Noelle C Anastasio; Kenneth M Johnson
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

View more
  9 in total

1.  Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain.

Authors:  Nina Segnitz; Thomas Ferbert; Andrea Schmitt; Peter Gass; Peter J Gebicke-Haerter; Mathias Zink
Journal:  Psychopharmacology (Berl)       Date:  2011-04-12       Impact factor: 4.530

Review 2.  The Regulation of GluN2A by Endogenous and Exogenous Regulators in the Central Nervous System.

Authors:  Yongjun Sun; Liying Zhan; Xiaokun Cheng; Linan Zhang; Jie Hu; Zibin Gao
Journal:  Cell Mol Neurobiol       Date:  2016-06-02       Impact factor: 5.046

Review 3.  Animal models of schizophrenia.

Authors:  C A Jones; D J G Watson; K C F Fone
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

4.  Metaplasticity gated through differential regulation of GluN2A versus GluN2B receptors by Src family kinases.

Authors:  Kai Yang; Catherine Trepanier; Bikram Sidhu; Yu-Feng Xie; Hongbin Li; Gang Lei; Michael W Salter; Beverley A Orser; Takanobu Nakazawa; Tadashi Yamamoto; Michael F Jackson; John F Macdonald
Journal:  EMBO J       Date:  2011-12-20       Impact factor: 11.598

Review 5.  Models of neurodevelopmental abnormalities in schizophrenia.

Authors:  Susan B Powell
Journal:  Curr Top Behav Neurosci       Date:  2010

Review 6.  Synapse-specific contributions in the cortical pathology of schizophrenia.

Authors:  Saurav Seshadri; Mariela Zeledon; Akira Sawa
Journal:  Neurobiol Dis       Date:  2013-01-18       Impact factor: 5.996

Review 7.  Antipsychotic treatment modulates glutamate transport and NMDA receptor expression.

Authors:  Mathias Zink; Susanne Englisch; Andrea Schmitt
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-12       Impact factor: 5.270

8.  Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder.

Authors:  Daniel R Rosell; Lauren C Zaluda; Margaret M McClure; M Mercedes Perez-Rodriguez; K Sloan Strike; Deanna M Barch; Philip D Harvey; Ragy R Girgis; Erin A Hazlett; Richard B Mailman; Anissa Abi-Dargham; Jeffrey A Lieberman; Larry J Siever
Journal:  Neuropsychopharmacology       Date:  2014-07-30       Impact factor: 7.853

9.  Anatomical transcriptome of G protein-coupled receptors leads to the identification of a novel therapeutic candidate GPR52 for psychiatric disorders.

Authors:  Hidetoshi Komatsu; Minoru Maruyama; Shuuhei Yao; Tokuyuki Shinohara; Kensuke Sakuma; Sachiko Imaichi; Tomoko Chikatsu; Kanako Kuniyeda; Foo Kok Siu; Lam Sock Peng; Katherine Zhuo; Lay Sock Mun; Tan Min Han; Yoshio Matsumoto; Tadatoshi Hashimoto; Nobuyuki Miyajima; Yasuaki Itoh; Kazuhiro Ogi; Yugo Habata; Masaaki Mori
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.